The European Medicines Agency's Pharmacovigilance Risk Assessment Committee has launched a safety review of all injectable iron medicines following reports of severe hypophosphatemia and osteomalacia. The review evaluates risks across formulations like ferric carboxymaltose, which clinical trials show has a higher rate of phosphate reduction than other treatments. Diagnosis is often delayed because symptoms overlap with iron deficiency and osteomalacia may not appear on standard x-rays.
Injectable iron safety review
- ▪The European Medicines Agency's Pharmacovigilance Risk Assessment Committee launched a safety review across all injectable iron formulations on September 7, 2026
- ▪The European Medicines Agency's safety review excludes oral iron supplements because they provide lower iron amounts and carry a lower risk for hypophosphatemia
- ▪The European Medicines Agency's safety review was prompted by reports of severe hypophosphatemia and osteomalacia linked to injectable iron medicines
Hypophosphatemia bone complications
- ▪Injectable iron medicines are used to treat iron deficiency and iron-deficiency anemia when oral supplements are inadequate, not tolerated, or too slow
- ▪Hypophosphatemia is a recognized adverse effect of ferric carboxymaltose, affecting up to 1 in 10 patients, but the frequency of hypophosphatemia-related osteomalacia remains unknown
- ▪Reports of osteomalacia linked to injectable iron medicines have occurred after only one or two doses and in patients with no recognized risk factors
Diagnostic symptom overlap
- ▪Osteomalacia caused by injectable iron medicines may not be visible on standard x-rays, further complicating timely diagnosis
- ▪Symptoms of low phosphate, such as fatigue, muscle pain, and bone pain, overlap with underlying iron deficiency symptoms, potentially delaying diagnosis
Ferric carboxymaltose evidence
- ▪A systematic review and meta-analysis found that hypophosphatemia persisted through study end points in up to 45% of patients treated with ferric carboxymaltose
- ▪A systematic review and meta-analysis of 42 clinical trials found hypophosphatemia occurred in 47% of patients treated with ferric carboxymaltose compared to 4% with iron isomaltoside
- ▪Preserved kidney function and markers of severe iron deficiency, including low baseline ferritin and transferrin saturation, were identified as significant predictors of hypophosphatemia
PRAC regulatory assessment
- ▪The Pharmacovigilance Risk Assessment Committee will assess whether the risks of hypophosphatemia affect the overall benefit-risk balance of injectable iron medicines
- ▪The final recommendations of the Pharmacovigilance Risk Assessment Committee will be forwarded to the Coordination Group for Mutual Recognition and Decentralised Procedures – Human
- ▪The Pharmacovigilance Risk Assessment Committee's evaluation includes injectable medicines containing ferric carboxymaltose, ferric derisomaltose, iron dextran, ferric gluconate, ferric hydroxide polymaltose complex, and iron sucrose
Story comments
Loading comments…